O	0	3	The
O	4	10	impact
O	11	13	of
B-intervention	14	22	exercise
O	23	25	on
O	26	32	growth
O	33	40	factors
O	41	42	(
O	42	46	VEGF
O	47	50	and
O	51	55	FGF2
O	55	56	)
O	56	57	:
O	58	65	results
O	66	70	from
O	71	72	a
O	73	75	12
O	75	76	-
O	76	81	month
O	82	92	randomized
O	93	105	intervention
O	106	111	trial
O	111	112	.

O	113	121	Vascular
O	122	133	endothelial
O	134	140	growth
O	141	147	factor
O	148	149	(
O	149	153	VEGF
O	153	154	)
O	155	158	and
O	159	169	Fibroblast
O	170	176	growth
O	177	183	factor
O	183	184	-
O	184	185	2
O	186	187	(
O	187	191	FGF2
O	191	192	)
O	193	196	are
O	197	207	angiogenic
O	208	217	cytokines
O	218	220	in
O	221	227	normal
O	228	235	tissues
O	236	239	and
O	240	246	tumors
O	246	247	.

O	248	256	Evidence
O	257	265	suggests
O	266	270	that
O	271	280	increased
O	281	287	growth
O	288	294	factor
O	295	305	expression
O	306	308	in
O	309	316	adipose
O	317	323	tissue
O	324	329	leads
O	330	332	to
O	333	341	improved
O	342	353	vascularity
O	354	357	and
O	358	367	decreased
O	368	375	hypoxia
O	375	376	,
O	377	385	fibrosis
O	385	386	,
O	387	390	and
O	391	403	inflammation
O	403	404	,
O	405	410	which
O	411	414	may
O	414	415	,
O	416	418	in
O	419	423	turn
O	423	424	,
O	425	431	reduce
O	432	436	post
O	436	437	-
O	437	447	menopausal
O	448	454	breast
O	455	461	cancer
O	462	466	risk
O	466	467	.

O	468	470	We
O	471	483	investigated
O	484	491	whether
O	492	494	or
O	495	498	not
O	499	507	exercise
O	508	511	had
O	512	516	dose
O	516	517	-
O	517	525	response
O	526	533	effects
O	534	536	on
O	537	543	levels
O	544	546	of
O	547	553	plasma
O	554	558	VEGF
O	559	562	and
O	563	567	FGF2
O	568	570	in
O	571	585	postmenopausal
O	586	591	women
O	591	592	.

B-total-participants	593	597	Four
I-total-participants	598	605	hundred
B-eligibility	606	616	previously
I-eligibility	617	625	inactive
I-eligibility	626	629	but
I-eligibility	630	637	healthy
I-eligibility	638	652	postmenopausal
I-eligibility	653	658	women
O	659	663	aged
B-age	664	666	50
I-age	666	667	-
I-age	667	669	74
I-age	670	675	years
O	676	678	of
O	679	682	age
O	683	687	were
O	688	698	randomized
O	699	701	to
O	702	705	150
O	706	708	or
O	709	712	300
O	713	716	min
O	717	720	per
O	721	725	week
O	726	728	of
O	729	736	aerobic
O	737	745	exercise
O	746	748	in
O	749	750	a
O	751	755	year
O	755	756	-
O	756	760	long
O	761	769	exercise
O	770	782	intervention
O	782	783	.

O	784	788	VEGF
O	789	792	and
O	793	797	FGF2
O	798	802	were
O	803	811	measured
O	812	816	from
O	817	824	fasting
O	825	830	serum
O	831	838	samples
O	839	843	with
O	844	845	a
O	846	852	custom
O	852	853	-
O	853	857	plex
O	858	867	multiplex
O	868	873	assay
O	873	874	.

O	875	876	A
O	877	881	high
O	882	890	compared
O	891	893	to
O	894	902	moderate
O	903	909	volume
O	910	912	of
O	913	920	aerobic
O	921	929	exercise
O	930	933	did
O	934	937	not
O	938	943	cause
O	944	951	chronic
B-outcome	952	959	changes
I-outcome	960	962	in
I-outcome	963	969	plasma
I-outcome	970	974	VEGF
I-outcome	975	977	or
I-outcome	978	982	FGF2
I-outcome	983	989	levels
O	990	992	in
O	993	1002	intention
O	1002	1003	-
O	1003	1005	to
O	1005	1006	-
O	1006	1011	treat
O	1012	1014	or
O	1015	1018	per
O	1018	1019	-
O	1019	1027	protocol
O	1028	1036	analyses
O	1036	1037	.

O	1038	1040	We
O	1041	1044	did
O	1045	1048	not
O	1049	1055	detect
B-outcome	1056	1067	differences
I-outcome	1068	1070	in
I-outcome	1071	1077	growth
I-outcome	1078	1084	factor
I-outcome	1085	1091	levels
O	1092	1099	related
O	1100	1102	to
O	1103	1113	increasing
O	1114	1119	doses
O	1120	1122	of
O	1123	1131	exercise
O	1131	1132	.

O	1133	1135	It
O	1136	1138	is
O	1139	1147	unlikely
O	1148	1152	that
O	1153	1160	changes
O	1161	1163	in
O	1164	1168	VEGF
O	1169	1172	and
O	1173	1177	FGF2
O	1178	1184	levels
O	1185	1192	mediate
O	1193	1196	the
O	1197	1206	reduction
O	1207	1209	in
O	1210	1214	risk
O	1215	1217	of
O	1218	1222	post
O	1222	1223	-
O	1223	1233	menopausal
O	1234	1240	breast
O	1241	1247	cancer
O	1248	1259	development
O	1260	1262	in
O	1263	1273	associated
O	1274	1278	with
O	1279	1288	increased
O	1289	1295	levels
O	1296	1298	of
O	1299	1307	exercise
O	1307	1308	.

O	1309	1323	Clinicaltrials
O	1323	1324	.
O	1324	1327	gov
O	1328	1338	identifier
O	1338	1339	:
O	1340	1351	NCT01435005
O	1351	1352	.
